Multiomic DNA Test for Heart Disease May Save Health Insurers Millions
Summary:
Takeaways:
- The use of the PrecisionCHD test for initial coronary heart disease assessment can lead to substantial cost reductions for healthcare providers and insurers, with potential savings of
$113.6 million per year for a health plan serving one million members. - PrecisionCHD utilizes a combination of six DNA methylation and ten genetic biomarkers analyzed through a proprietary machine learning model. It has shown a sensitivity of 79% and specificity of 76%, indicating its effectiveness in accurately detecting stable CHD.
- The test has received a Current Procedural Terminology (CPT) code from the
American Medical Association and an Innovation Technology contract fromVizient .
The peer-reviewed study “The Use of Precision Epigenetic Methods for the Diagnosis and Care of Stable Coronary Heart Disease Reduces Healthcare Costs” published in Advances in Therapy, reported that the use of PrecisionCHD can significantly reduce the cost of secondary prevention for stable coronary heart disease (CHD) by up to
AI-Powered DNA Test for Coronary Heart Disease
PrecisionCHD is an AI-powered multiomic DNA test using epigenetic and genetic biomarkers to aid in the detection of stable coronary heart disease. This blood-based test evaluates six DNA methylation and ten genetic biomarkers and uses a proprietary machine learning model to interpret the genetically contextual methylation signals from these biomarkers. The sensitivity and specificity of this test are 79% and 76%, respectively, with the clinical validation study in collaboration with
Cost Savings for Coronary Heart Disease Testing
The PrecisionCHD budget impact model was designed to evaluate the cost savings associated with using PrecisionCHD as the primary method of initial coronary heart disease assessment in place of current commonly used tests such as exercise electrocardiograms, coronary computed tomography angiography (CCTA), and angiograms. The model considered factors such as the number of tests performed, the cost of each test, and the impact of test results on treatment decisions. The results suggest that using PrecisionCHD could lead to significant cost savings for payers, with an estimated
“The data from this study suggests that the broader use of PrecisionCHD as the initial test for detecting coronary heart disease can yield significant savings to payers,” says
PrecisionCHD was recently awarded the Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code, 0449U, by the


NC health plan discriminates against transgender workers, federal appeals court rules [The Charlotte Observer]
Fewer Californians Buying Flood Insurance Despite Record-Breaking Year | Insurify
Advisor News
- NAIFA applauds final SECURE 2.0 regulations
- What will Democrats in Congress do about healthcare and retirement?
- Election results cloud retirement legislation outlook, experts say
- Planning for the missing chapter
- Semi-retirement: helping clients balance flexibility with financial security
More Advisor NewsAnnuity News
- ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
- Jackson Launches Direct-to-Consumer Annuity Offering
- Global Atlantic launches ForeIncome Flex
- Athene CEO criticizes offshore reinsurance, risk-taking by competitors
- DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
More Annuity NewsHealth/Employee Benefits News
- REP. ONDER INTRODUCES THE ALLERGY AND ASTHMA PATIENT PROTECTION ACT
- Forms, phone calls and portals: The hidden work that keeps American institutions functioning burdens parents most
- What will Democrats in Congress do about healthcare and retirement?
- Forms, phone calls and portals: The hidden work that keeps American institutions functioning burdens parents most
- Health Plans Expect Double-Digit Premium Increases Again in 2027
More Health/Employee Benefits NewsLife Insurance News
- California’s new solvency rules: What should life insurance advisors watch?
- Navigating delayed death certificates: A guide for life insurance advisors
- Jackson Launches Direct-to-Consumer Annuity Offering
- Best’s Market Segment Report: AM Best Maintains Stable Outlook on New Zealand’s Non-Life Insurance Segment
- AM Best Affirms Credit Ratings of Fubon Insurance Vietnam Co., Ltd.
More Life Insurance News